Quoin Pharmaceuticals Ltd... (QNRX)
| Bid | 0.22 |
| Market Cap | 2M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -12.31M |
| EPS (ttm) | -1.91 |
| PE Ratio (ttm) | -0.12 |
| Forward PE | -0.19 |
| Analyst | Buy |
| Ask | 0.25 |
| Volume | 285,729 |
| Avg. Volume (20D) | 5,551,696 |
| Open | 0.24 |
| Previous Close | 0.24 |
| Day's Range | 0.22 - 0.24 |
| 52-Week Range | 0.22 - 1.57 |
| Beta | 1.59 |
About QNRX
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia....
Analyst Forecast
According to 1 analyst ratings, the average rating for QNRX stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 1686.51% from the latest price.
Stock Forecasts
2 months ago · accessnewswire.com
Skinvisible Reports Licensee Success in Netherton Syndrome Clinical StudiesLAS VEGAS, NV / ACCESS Newswire / January 23, 2025 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical and transdermal pharmaceutical research and...